Medical centers declining to administer an FDA-approved drug is rare, and controversy surrounding the Alzheimer’s drug Aduhelm has led to questions about the approval process, and even value-based care.
Medical centers declining to administer an FDA-approved drug is rare, and controversy surrounding the Alzheimer’s drug Aduhelm has led to questions about the approval process, and even value-based care.
Copyright © 2024 | WordPress Theme by MH Themes